Condition: AML, Adult · Sponsor: Zhejiang University
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 target CAR iPSC NK cells in patients with relapsed/refractory AML
This description comes directly from the study's public registry record.
He Huang, MD · +8613605714822 · hehuangyu@126.com
Yongxian Hu, MD · +8615957162012 · huyongxian2000@aliyun.com
Always discuss trial participation with your own doctor first.
| Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06027853